BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33918307)

  • 1. Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
    Spinello Z; Fregnani A; Quotti Tubi L; Trentin L; Piazza F; Manni S
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.
    Manni S; Carrino M; Piazza F
    J Hematol Oncol; 2017 Oct; 10(1):157. PubMed ID: 28969692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
    Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
    Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casein kinase 1α: biological mechanisms and theranostic potential.
    Jiang S; Zhang M; Sun J; Yang X
    Cell Commun Signal; 2018 May; 16(1):23. PubMed ID: 29793495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.
    Bowman BM; Sebolt KA; Hoff BA; Boes JL; Daniels DL; Heist KA; Galbán CJ; Patel RM; Zhang J; Beer DG; Ross BD; Rehemtulla A; Galbán S
    Sci Signal; 2015 Jan; 8(361):ra9. PubMed ID: 25628462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Casein Kinase 1 (CK1) in Hematological Cancers.
    Janovská P; Normant E; Miskin H; Bryja V
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major tegument protein VP8 of bovine herpesvirus 1 is phosphorylated by viral US3 and cellular CK2 protein kinases.
    Labiuk SL; Babiuk LA; van Drunen Littel-van den Hurk S
    J Gen Virol; 2009 Dec; 90(Pt 12):2829-2839. PubMed ID: 19692545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.
    Zhang F; Virshup DM; Cheong JK
    Oncogene; 2018 Jan; 37(3):363-376. PubMed ID: 28945225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casein kinases as potential therapeutic targets.
    Cozza G; Pinna LA
    Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of CK2 in acute and chronic leukemias.
    Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
    Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP site-directed inhibitors of protein kinase CK2: an update.
    Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
    Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
    Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
    Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
    Ruzzene M; Pinna LA
    Biochim Biophys Acta; 2010 Mar; 1804(3):499-504. PubMed ID: 19665589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers.
    Cheong JK; Zhang F; Chua PJ; Bay BH; Thorburn A; Virshup DM
    J Clin Invest; 2015 Apr; 125(4):1401-18. PubMed ID: 25798617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophosphorylation of carboxy-terminal residues inhibits the activity of protein kinase CK1alpha.
    Budini M; Jacob G; Jedlicki A; Pérez C; Allende CC; Allende JE
    J Cell Biochem; 2009 Feb; 106(3):399-408. PubMed ID: 19115251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
    Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of synthetic fragments of inhibitor-2 of protein phosphatase-1 by casein kinase-1 and -2. Evidence that phosphorylated residues are not strictly required for efficient targeting by casein kinase-1.
    Marin O; Meggio F; Sarno S; Andretta M; Pinna LA
    Eur J Biochem; 1994 Jul; 223(2):647-53. PubMed ID: 8055935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
    Duncan JS; Litchfield DW
    Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer.
    Husain K; Williamson TT; Nelson N; Ghansah T
    Immunol Med; 2021 Sep; 44(3):159-174. PubMed ID: 33164702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.